Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Nie, Z., Feher, V., Natala, S., McBride, C., Kiryanov, A., Jones, B., Lam, B., Liu, Y., Kaldor, S., Stafford, J., Hikami, K., Uchiyama, N., Kawamoto, T., Hikichi, Y., Matsumoto, S., Amano, N., Zhang, L., Hosfield, D., Skene, R., Zou, H., Cao, X., Ichikawa, T.(2013) Bioorg Med Chem Lett 23: 3662-3666
- PubMed: 23664874 
- DOI: https://doi.org/10.1016/j.bmcl.2013.02.083
- Primary Citation of Related Structures:  
4J52, 4J53 - PubMed Abstract: 
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.
Organizational Affiliation: 
Takeda California, 10410 Science Center Drive, San Diego, CA 92121, USA.